Potential Therapeutic Agents for COVID-19 Based on the Analysis of Protease and RNA Polymerase Docking
Version 2 : Received: 27 February 2020 / Approved: 29 February 2020 / Online: 29 February 2020 (12:43:40 CET)
How to cite: Chang, Y.-C.; Tung, Y.-A.; Lee, K.-H.; Chen, T.-F.; Hsiao, Y.-C.; Chang, H.-C.; Hsieh, T.-T.; Su, C.-H.; Wang, S.-S.; Yu, J.-Y.; Shih, S.-S.; Lin, Y.-H.; Lin, Y.-H.; Tu, Y.-C. E.; Hsu, C.-H.; Juan, H.-F.; Tung, C.-W.; Chen, C.-Y. Potential Therapeutic Agents for COVID-19 Based on the Analysis of Protease and RNA Polymerase Docking. Preprints 2020, 2020020242. https://doi.org/10.20944/preprints202002.0242.v2 Chang, Y.-C.; Tung, Y.-A.; Lee, K.-H.; Chen, T.-F.; Hsiao, Y.-C.; Chang, H.-C.; Hsieh, T.-T.; Su, C.-H.; Wang, S.-S.; Yu, J.-Y.; Shih, S.-S.; Lin, Y.-H.; Lin, Y.-H.; Tu, Y.-C. E.; Hsu, C.-H.; Juan, H.-F.; Tung, C.-W.; Chen, C.-Y. Potential Therapeutic Agents for COVID-19 Based on the Analysis of Protease and RNA Polymerase Docking. Preprints 2020, 2020020242. https://doi.org/10.20944/preprints202002.0242.v2
Abstract
Keywords
Subject
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (1)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
Commenter: Chien-Yu Chen
Commenter's Conflict of Interests: Author
For the top-ranked nucleoside analogue - Redemsivir, we further examined its different formations, including Remdesivir (Nucleoside Analogue Monophosphate Prodrug with Protect Group), GS441524 (Nucleoside Analogue) and CHEMBL2016761 (Nucleoside Analogue Triphosphate), since Redemsivir is a prodrug. The results showed that CHEMBL2016761, the active form of nucleoside analogues, which is activated by blocking viral replication, still has a good docking score. Moreover, the docking site of CHEMBL2016761 is perfectly located in the NTP binding motif, which suggested Redemsivir could be a potential therapeutic agent.
Commenter: Ryad Boukadoum
The commenter has declared there is no conflict of interests.
First of all thank you for sharing this very interesting article.
I wish you all the best
My question is the following:
Is there any link between VIH and Covod 19 taking into consideration the genetic structure?
Thank you !
Best regards
Ryad